gamma-aminobutyric acid has been researched along with Kidney Diseases in 14 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of gabapentin for the treatment of uremic pruritus (UP)." | 7.74 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "Literature retrieval was accessed through MEDLINE (1950-March week 3, 2008; In-Process & Other Non-Indexed Citations, April 1, 2008) and International Pharmaceutical Abstracts (1970-March 2008) using the terms gabapentin, pruritus, itch, urem$ (truncated), dialysis, and kidney disease." | 7.74 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "Gabapentin has been evaluated for the treatment of UP in 2 small, randomized, placebo-controlled studies, 1 pilot evaluation, and 1 index case." | 5.35 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| " Further well-designed trials are warranted to establish the most appropriate dosing regimen in patients on HD." | 5.35 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "Gamma-aminobutyric acid (GABA) was administered orally to rats for 60 d after excision of five-sixths of their kidney volume." | 5.34 | Gamma-aminobutyric acid specifically inhibits progression of tubular fibrosis and atrophy in nephrectomized rats. ( Kim, M; Sasaki, S; Tohda, C; Yokozawa, T, 2007) |
| "To evaluate the efficacy of gabapentin for the treatment of uremic pruritus (UP)." | 3.74 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "Literature retrieval was accessed through MEDLINE (1950-March week 3, 2008; In-Process & Other Non-Indexed Citations, April 1, 2008) and International Pharmaceutical Abstracts (1970-March 2008) using the terms gabapentin, pruritus, itch, urem$ (truncated), dialysis, and kidney disease." | 3.74 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "The objective of this study was to describe a population pharmacokinetic analysis of gabapentin enacarbil in patients with varying degrees of renal function, using data from an open-label study of gabapentin enacarbil in patients with renal impairment (XenoPort, Inc." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " Pharmacokinetic data were compared with those from Phase I-III studies in subjects with normal renal function to evaluate the relationship between gabapentin oral clearance (CL/F) and CrCL." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " Based on the population pharmacokinetic analysis, gabapentin CL/F after administration of gabapentin enacarbil was proportionally related to CrCL, with an approximately 1." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " protocol XP066), to determine whether dosage adjustments are necessary in patients with renal impairment." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| "The data suggest that dosage adjustment for gabapentin enacarbil is necessary in patients with impaired renal function." | 2.77 | Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ( Blumenthal, R; Chen, D; Cundy, KC; Ho, J; Lal, R; Luo, W; Sukbuntherng, J, 2012) |
| " The plasma VGB concentration-time data were analyzed by mixed-effects modeling to estimate population pharmacokinetic parameters and to identify any significant demographic covariates." | 2.67 | A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data. ( Bhargava, VO; Hutcheson, SJ; Wei, G; Weir, SJ; Yu, DK, 1994) |
| "Gabapentin has been evaluated for the treatment of UP in 2 small, randomized, placebo-controlled studies, 1 pilot evaluation, and 1 index case." | 1.35 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| " Further well-designed trials are warranted to establish the most appropriate dosing regimen in patients on HD." | 1.35 | Role of gabapentin in the treatment of uremic pruritus. ( Gommer, J; Scates, AC; Vila, T, 2008) |
| "Gamma-aminobutyric acid (GABA) was administered orally to rats for 60 d after excision of five-sixths of their kidney volume." | 1.34 | Gamma-aminobutyric acid specifically inhibits progression of tubular fibrosis and atrophy in nephrectomized rats. ( Kim, M; Sasaki, S; Tohda, C; Yokozawa, T, 2007) |
| "Gabapentin CL/F and CLR were linearly correlated with creatinine clearance." | 1.29 | Pharmacokinetics of gabapentin in subjects with various degrees of renal function. ( Blum, RA; Bockbrader, H; Busch, JA; Comstock, TJ; Keller, E; Reece, PA; Reetze, P; Schultz, RW; Sica, DA; Tuerck, D, 1994) |
| " Apparent oral plasma clearance (CL/F) and renal clearance (CLR) of gabapentin decreased and maximum plasma concentration, time to reach maximum concentration, and half-life values increased as renal function diminished." | 1.29 | Pharmacokinetics of gabapentin in subjects with various degrees of renal function. ( Blum, RA; Bockbrader, H; Busch, JA; Comstock, TJ; Keller, E; Reece, PA; Reetze, P; Schultz, RW; Sica, DA; Tuerck, D, 1994) |
| " Based on pharmacokinetic considerations, it appears that the dosing regimen of gabapentin in subjects with renal impairment may be adjusted on the basis of creatinine clearance." | 1.29 | Pharmacokinetics of gabapentin in subjects with various degrees of renal function. ( Blum, RA; Bockbrader, H; Busch, JA; Comstock, TJ; Keller, E; Reece, PA; Reetze, P; Schultz, RW; Sica, DA; Tuerck, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Favero, C | 1 |
| Giordano, L | 1 |
| Mihaila, SM | 1 |
| Masereeuw, R | 1 |
| Ortiz, A | 1 |
| Sanchez-Niño, MD | 1 |
| Assadsangabi, R | 1 |
| Hajmomenian, M | 1 |
| Nabavizadeh, SA | 1 |
| Vossough, A | 1 |
| Kobuchi, S | 1 |
| Shintani, T | 1 |
| Sugiura, T | 1 |
| Tanaka, R | 1 |
| Suzuki, R | 1 |
| Tsutsui, H | 1 |
| Fujii, T | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Lal, R | 1 |
| Sukbuntherng, J | 1 |
| Luo, W | 1 |
| Chen, D | 1 |
| Blumenthal, R | 1 |
| Ho, J | 1 |
| Cundy, KC | 1 |
| Shahan, JL | 1 |
| Panu, LD | 1 |
| Hildebrandt, GC | 1 |
| Fitsanakis, VA | 1 |
| Aschner, M | 1 |
| Holtkamp, M | 1 |
| Halle, A | 1 |
| Meierkord, H | 1 |
| Masuhr, F | 1 |
| Sasaki, S | 1 |
| Tohda, C | 1 |
| Kim, M | 1 |
| Yokozawa, T | 1 |
| Vila, T | 1 |
| Gommer, J | 1 |
| Scates, AC | 1 |
| Yu, DK | 1 |
| Hutcheson, SJ | 1 |
| Wei, G | 1 |
| Bhargava, VO | 1 |
| Weir, SJ | 1 |
| Blum, RA | 1 |
| Comstock, TJ | 1 |
| Sica, DA | 1 |
| Schultz, RW | 1 |
| Keller, E | 1 |
| Reetze, P | 1 |
| Bockbrader, H | 1 |
| Tuerck, D | 1 |
| Busch, JA | 1 |
| Reece, PA | 1 |
| Grunze, H | 1 |
| Dittert, S | 1 |
| Bungert, M | 1 |
| Erfurth, A | 1 |
| Dominick, MA | 1 |
| Robertson, DG | 1 |
| Bleavins, MR | 1 |
| Sigler, RE | 1 |
| Bobrowski, WF | 1 |
| Gough, AW | 1 |
| Perry, TL | 1 |
| Yong, VW | 1 |
| Godolphin, WJ | 1 |
| Sutter, M | 1 |
| Hansen, S | 1 |
| Kish, SJ | 1 |
| Foulks, JG | 1 |
| Ito, M | 1 |
2 reviews available for gamma-aminobutyric acid and Kidney Diseases
| Article | Year |
|---|---|
Postbiotics and Kidney Disease.
Topics: gamma-Aminobutyric Acid; Humans; Kidney Diseases; Prebiotics; Probiotics; Synbiotics | 2022 |
The importance of glutamate, glycine, and gamma-aminobutyric acid transport and regulation in manganese, mercury and lead neurotoxicity.
Topics: Animals; Biological Transport; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Humans; Kidney Disea | 2005 |
2 trials available for gamma-aminobutyric acid and Kidney Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Topics: Administration, Oral; Adult; Aged; Analgesics; Anticonvulsants; Biomarkers; Biotransformation; Carba | 2012 |
A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data.
Topics: 4-Aminobutyrate Transaminase; Administration, Oral; Adolescent; Adult; Aged; Anticonvulsants; Cohort | 1994 |
10 other studies available for gamma-aminobutyric acid and Kidney Diseases
| Article | Year |
|---|---|
Deep renal ectopia causing sciatic mononeuropathy.
Topics: Adolescent; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma | 2014 |
Renoprotective effects of gamma-aminobutyric acid on ischemia/reperfusion-induced renal injury in rats.
Topics: Animals; Baclofen; Benzylamines; GABA Agonists; GABA Antagonists; GABA-B Receptor Antagonists; gamma | 2009 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combi | 2012 |
Gabapentin-induced severe myoclonus in a patient with impaired renal function.
Topics: Aged; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Kidney Disea | 2006 |
Gamma-aminobutyric acid specifically inhibits progression of tubular fibrosis and atrophy in nephrectomized rats.
Topics: Animals; Atrophy; Blood Urea Nitrogen; Creatinine; Disease Progression; Dose-Response Relationship, | 2007 |
Role of gabapentin in the treatment of uremic pruritus.
Topics: Amines; Antipruritics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Kid | 2008 |
Pharmacokinetics of gabapentin in subjects with various degrees of renal function.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Amines; Creatinine; Cyclohexanecarboxylic A | 1994 |
Renal impairment as a possible side effect of gabapentin. A single case report.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug Thera | 1998 |
Alpha 2u-globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(aminomethyl)cyclohexaneacetic acid.
Topics: Acetates; Alpha-Globulins; Amines; Animals; Chromatography, Gel; Cyclohexanecarboxylic Acids; Dose-R | 1991 |
Inability to produce a model of dialysis encephalopathy in the rat by aluminum administration.
Topics: Aluminum Hydroxide; Animals; Brain Chemistry; Brain Diseases; Choline O-Acetyltransferase; Disease M | 1987 |